AR104967A1 - Polinucleótido aislado, vector recombinante, adenovirus recombinante y composición que lo comprenden y su uso para preparar un medicamento - Google Patents

Polinucleótido aislado, vector recombinante, adenovirus recombinante y composición que lo comprenden y su uso para preparar un medicamento

Info

Publication number
AR104967A1
AR104967A1 ARP160101737A ARP160101737A AR104967A1 AR 104967 A1 AR104967 A1 AR 104967A1 AR P160101737 A ARP160101737 A AR P160101737A AR P160101737 A ARP160101737 A AR P160101737A AR 104967 A1 AR104967 A1 AR 104967A1
Authority
AR
Argentina
Prior art keywords
composition
recombinant
amino acid
acid sequence
isolated
Prior art date
Application number
ARP160101737A
Other languages
English (en)
Inventor
Vitelli Alessandra
Nicosia Alfredo
Grazioli Fabiana
Cortese Riccardo
Colloca Stefano
Ammendola Virginia
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of AR104967A1 publication Critical patent/AR104967A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un polinucleótido aislado, derivado del adenovirus de chimpancé ChAd155, donde el polinucleótido codifica un polipéptido seleccionado del grupo que consiste en: (a) un polipéptido que tiene la secuencia de aminoácidos de acuerdo con la SEQ ID Nº 1, (b) un derivado funcional de un polipéptido que tiene la secuencia de aminoácidos de acuerdo con la SEQ ID Nº 1, donde el derivado funcional tiene una secuencia de aminoácidos que es al menos 80% idéntica, en toda su longitud, a la secuencia de aminoácidos de SEQ ID Nº 1, y (c) un polipéptido que tiene la secuencia de aminoácidos de acuerdo con la SEQ ID Nº 3. Vector recombinante, adenovirus recombinante o composición que comprende dicho polinucleótido.
ARP160101737A 2015-06-12 2016-06-10 Polinucleótido aislado, vector recombinante, adenovirus recombinante y composición que lo comprenden y su uso para preparar un medicamento AR104967A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1510357.5A GB201510357D0 (en) 2015-06-12 2015-06-12 Adenovirus polynucleotides and polypeptides

Publications (1)

Publication Number Publication Date
AR104967A1 true AR104967A1 (es) 2017-08-30

Family

ID=53784650

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP160101736A AR104966A1 (es) 2015-06-12 2016-06-10 Polinucleótido aislado, polinucleótido recombinante, vector recombinante y adenovirus recombinante y célula que lo comprenden, composición que los comprende y polipéptido codificado por el mismo
ARP160101737A AR104967A1 (es) 2015-06-12 2016-06-10 Polinucleótido aislado, vector recombinante, adenovirus recombinante y composición que lo comprenden y su uso para preparar un medicamento

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP160101736A AR104966A1 (es) 2015-06-12 2016-06-10 Polinucleótido aislado, polinucleótido recombinante, vector recombinante y adenovirus recombinante y célula que lo comprenden, composición que los comprende y polipéptido codificado por el mismo

Country Status (2)

Country Link
AR (2) AR104966A1 (es)
GB (1) GB201510357D0 (es)

Also Published As

Publication number Publication date
AR104966A1 (es) 2017-08-30
GB201510357D0 (en) 2015-07-29

Similar Documents

Publication Publication Date Title
EA201792651A1 (ru) Аденовирусные полинуклеотиды и полипептиды
PH12020550051A1 (en) Glp-1 compositions and uses thereof
PE20190335A1 (es) Receptores de celulas t
EA201791426A1 (ru) Полипептид и иммуномодуляция
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
MX2017004488A (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
AR110502A1 (es) Polinucleótidos y polipéptidos de adenovirus
ECSP15042898A (es) Péptidos y composiciones para el tratamiento de daño articular
BR112017007202A2 (pt) receptores de célula t
NI201600028A (es) Polipéptido para la escisión hidrolítica de la zearalenona y/o derivados de la zearalenona, polinucleótido aislado de la misma y poliéptido que contiene aditivo, uso y procedimiento de los mismos.
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
CL2019003404A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico.(divisional solicitud 201702407)
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
AR101742A1 (es) Agonista del receptor de calcitonina y amilina
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
EA201990298A1 (ru) Способы и композиции для лечения рака
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
AR099068A1 (es) Anticuerpo anti-netrina-1
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
CL2017003097A1 (es) Composiciones y métodos para el tratamiento de la enfermedad celiaca
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
CL2018000164A1 (es) Vector recombinante del virus orf.
AR101146A1 (es) Proteína con actividad xilanasa
AR103586A1 (es) Proteínas quiméricas que mejoran la actividad de los dominios de unión a adn y factores de transcripción en plantas

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FB Suspension of granting procedure